Here’s a copy of the talk I gave at the American Chemical Society meeting, on using patent information to track globalization:
Check out it. I think the findings will surprise you!
I will be giving a talk on “Using patent information to track globalization” at the ACS conference in Anaheim next week. The talk is part of the ACS Division of Chemistry and Law session on What Can Patent Information Do For Scientists, and is based on analysis of data from DrugPatentWatch. I look forward to meeting BiotechBlog readers who may be in attendance. For those who cannot make the event, my talk will be based on my work on globalization of pharmaceutical innovation.
Fortune magazine recently published an article on the growing trend of generic companies challenging pharmaceutical drug patents. I enjoyed working with the writer to help layout the industry landscape, and share my knowledge of drug patents and trends from DrugPatentWatch.com. It’s a good read, and it does an excellent job of laying out the legal, regulatory, and economic mess that the pharmaceutical industry has become.
I had the pleasure of serving as a judge for last year’s Biotech Humanitarian Award, and now it’s time for nomination’s for this year’s award. The Award will be given to an individual who, through their work in or support of biotechnology, is harnessing its potential to heal, fuel or feed the planet.
In the words of BIO President and CEO Jim Greenwood. “The Biotech Humanitarian Award offers us the opportunity to highlight our biotech innovators – the men and women who are pioneering real solutions to improve people’s lives and the health of our planet.” The Humanitarian Award honors work that aims to reduce human suffering significantly or enhance the human experience in a way that has a clear and direct benefit to society. Additional consideration will be given to approaches that are at a turning point and may potentially have immeasurable influence.
Last year’s Award was bestowed upon Robert Klein, chairman of the governing board of the California Institute of Regenerative Medicine (CIRM). Klein is best known as the author and Chairman of California’s Proposition 71, the $6 billion “California Stem Cell Research and Cures” ballot initiative, which supports research with a focus on pluripotent (embryonic) and progenitor stem cell research. As chairman of CIRM, Klein manages the peer review and grant process for the $3 billion in stem cell research funding authorized by the Initiative.
The inaugural Award was bestowed upon Dr. Jay Keasling, CEO of the Joint BioEnergy Institute, Professor of Chemical Engineering and Bioengineering at the University of California at Berkley and acting Deputy Director of the Lawrence Berkeley National Laboratory. Keasling was honored for his break-through work in synthetic biology, which at commercial scale, will allow for lower cost access to first-line treatment for malaria, as well as significantly advance production of the next generation of biofuels. Keasling has previously said that he expects the new malaria treatment to be released at the end of 2011 or in early 2012.
The Award and a prize of $10,000 will be presented at the 2011 BIO International Convention, in Washington, DC on June 27-30, 2011. Nominations are open to all individuals and can be accessed via http://biotech-now.org/humanitarian-award-nomination. Nominees will be evaluated and judged on the following criteria: Impact on future generations; Impact on contemporary society; Contribution to the field of biotechnology; and Level of innovation exhibited.
Qualified nominees for the Biotech Humanitarian Award will be professionals in the biotechnology field including scientists, researchers, academics, entrepreneurs, financiers, philanthropists, educators, advocates and others who have added value to society through their pursuit of biotechnology processes.
*Drugs may be covered by multiple patents
|Tradename||Applicant||Generic Name||Patent Number||Patent Expiration|
|AZOPT||Alcon||brinzolamide||5,240,923*PED||Mar 1, 2011|
|SYMLIN||Amylin||pramlintide acetate||6,610,824||Mar 3, 2011|
|NITROLINGUAL PUMPSPRAY||Pohl Boskamp||nitroglycerin||5,186,925||Mar 6, 2011|
|SYMLIN||Amylin||pramlintide acetate||6,610,824||Mar 8, 2011|
|SYMLIN||Amylin||pramlintide acetate||7,407,934||Mar 8, 2011|
|SYMLIN||Amylin||pramlintide acetate||5,998,367||Mar 8, 2011|
|VANTAS||Endo Pharm||histrelin acetate||5,292,515||Mar 8, 2011|
|SUPPRELIN LA||Endo Pharm||histrelin acetate||5,292,515||Mar 8, 2011|
|SYMLIN||Amylin||pramlintide acetate||7,271,238||Mar 8, 2011|
|FOLLISTIM||Organon Usa Inc||follitropin alfa/beta||5,270,057||Mar 20, 2011|
|PROSCAR||Merck||finasteride||6,046,183||Mar 20, 2011|
|FAMVIR||Novartis||famciclovir||5,246,937*PED||Mar 21, 2011|
|XALATAN||Pharmacia And Upjohn||latanoprost||5,422,368||Mar 22, 2011|
|XALATAN||Pharmacia And Upjohn||latanoprost||5,296,504||Mar 22, 2011|
|ENTEREG||Adolor||alvimopan||5,250,542||Mar 29, 2011|
In this recent video from Biotech Showcase 2011. My good friend Stan Yakatan provides his perspectives on his decades spent in the biotechnology industry. Check it out; he’s got some excellent insights.
I have selected these management-themed articles from the Journal of Commercial Biotechnology, exploring the practical aspects of product innovation, R&D, patent law and marketing. The collection is divided into distinct sections: Commentary; Policy; Commercial Strategy; Valuation/Licensing; Funding; Intellectual Property; International; and Case Studies.
These articles are only fully readable for a limited period of time, so please feel free to read, download and forward them on to your colleagues while they are still available.
You can view the full collection on the Journal’s website: alternatively, the articles included in this collection are listed below:
Why data exclusivity is the new patent protection
Peter J Pitts
Public–private partnerships in trust-based public health social networking: Connecting organizations for regional disease surveillance (CORDS)
Louise S Greshama, Leslie A Pray, Suwit Wibulpolprasert, Beverly Trayner
Building biotechnology in Okinawa
Revitalizing portfolio decision-making at Merck Serono S.A.
Vincent Aurentz, Bernhard Kirschbaum and Markus Thunecke
Building biotechnology teams: Personality does matter
Anne S York, Kim A McCarthy and Todd C Darnold
Pharmaceutical royalties in licensing deals: No place for the 25 per cent rule of thumb
Nigel Borshell and Adrian Dawkes
Valuation of complex license contracts
Ralph Villiger and Boris Bogdan
R&D spending and sources of funding of private US biopharmaceutical firms seeking to go public
David R Williams and Richard W Pouder
When should you fire the founder
Dominating global intellectual property: Overview of patentability in the USA, Europe and Japan
Thomas J Kowalski, Antonio Maschio and Samuel H Megerditchian
Biotechnology in Cuba: 20 years of scientific, social and economic progress
Ernesto López Mola, Ricardo Silva, Boris Acevedo, José A Buxadó, Angel Aguilera and Luis Herrera
China 10-Point Patent Checklist: Integrating patents into an overall business strategy for a Western manufacturing entity in China
Catherine Sun, Sharon R Barner and Harold C Wegner
Beacon Sciences: Commercialisation from biothreat detection to beauty enhancement
Rob Hanes, Damon Borich
The February 2011 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract for each paper:
Volume 17, Issue 1
|Applying design thinking to biotechnology|
|Building biotechnology by design: An entrepreneur’s perspective|
|Arthur A Boni|
|Building biotechnology by design: Role of biotechnology in development|
|Pricing biologics: Issues, strategic priorities and a conceptual model|
|Sanjay K Rao|
|Revitalizing portfolio decision-making at Merck Serono S.A. – Geneva|
|Vincent Aurentz, Bernhard Kirschbaum, Markus Thunecke|
|Global consensus – Need of the hour for genetically modified organisms (GMO) labeling|
|Beyond investment: Advancing the biotechnology sector in the countries of the Gulf Cooperation Council (GCC)|
|Leonard Lerer, Brett Bowman|
|Repurposing of the epidermal growth factor|
|Ernesto L Mola, José A Buxadó, Luis Herrera|
|Biotechnology commercialization: A case study from Central and Eastern Europe|
|Dana Ukropcova, Ernest Sturdik|
|The developments in the business models of biotechnology in the Central and Eastern European countries: The example of Estonia|
|EU Legal and Regulatory Update|